<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02697838</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD-G323</org_study_id>
    <nct_id>NCT02697838</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer</brief_title>
  <official_title>Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single arm study: Apatinib plus paclitaxel as the reverses treatment in advanced gastric&#xD;
      cancer which paclitaxel-resistant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial investigated the efficacy and safety of apatinib plus paclitaxel, as a treatment&#xD;
      option for patients with advanced gastric cancer which paclitaxel-resistant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">August 1, 2016</start_date>
  <completion_date type="Anticipated">October 31, 2018</completion_date>
  <primary_completion_date type="Actual">March 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease control rate(DCR)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Malignant Neoplasm of Stomach Stage II</condition>
  <arm_group>
    <arm_group_label>Experimental: Apatinib plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib (850 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.</description>
    <arm_group_label>Experimental: Apatinib plus chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel-based chemotherapeutic regimens</intervention_name>
    <description>Paclitaxel-based chemotherapeutic regimens including:&#xD;
The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.&#xD;
The PF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.&#xD;
Paclitaxel 80mg/m2 d1，d8，d15，repeating the cycle every 28 days&#xD;
other paclitaxel-based regimens</description>
    <arm_group_label>Experimental: Apatinib plus chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: more than 18 years old;&#xD;
&#xD;
          2. Histologically confirmed advanced or metastatic adenocarcinoma of gastric cancer(AGC)&#xD;
             , including adenocarcinoma of the gastroesophageal junction;&#xD;
&#xD;
          3. At least one measurable and evaluable disease based on response evaluation criteria in&#xD;
             solid tumors (RECIST v1.1);&#xD;
&#xD;
          4. The patient with Prior Paclitaxel-Resistant;&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2;&#xD;
&#xD;
          6. An expected survival of ≥ 3 months;&#xD;
&#xD;
          7. Duration from the last therapy is more than 6 weeks for nitroso or mitomycin, More&#xD;
             than 4 weeks for other cytotoxic agents, operation or radiotherapy;&#xD;
&#xD;
          8. Major organ function has to meet the following criteria; (1) For results of blood&#xD;
             routine test:&#xD;
&#xD;
               1. Hemoglobin (HB) ≥ 80g / L,&#xD;
&#xD;
               2. ANC ≥ 1.5 × 109 / L,&#xD;
&#xD;
               3. PLT ≥ 75 × 109 / L, (2) For results of biochemical tests:&#xD;
&#xD;
               1. BLT ≤ 1.25 times the upper limit of normal (ULN),&#xD;
&#xD;
               2. ALT and AST ≤ 2.5 × ULN, liver metastases, if any, the ALT and AST≤ 5 × ULN,&#xD;
&#xD;
               3. Serum Cr≤1ULN, Endogenous creatinine clearance rate &gt;50ml/min;&#xD;
&#xD;
          9. Pregnancy test (serum or urine) has to be performed for woman of childbearing age&#xD;
             within 7 days before enrolment and the test result must be negative. They shall take&#xD;
             appropriate methods for contraception during the study until the 8th week post the&#xD;
             last administration of study drug. For men, (previous surgical sterilization&#xD;
             accepted), shall agree to take appropriate methods of contraception during the study&#xD;
             until the 8th week post the last administration of study drug;&#xD;
&#xD;
         10. Patient has to voluntarily join the study and sign the Informed Consent Form for the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of other malignancies except cured basal cell carcinoma of skin and carcinoma&#xD;
             insitu of uterine cervix;&#xD;
&#xD;
          2. Confirmed that apatinib and/or its accessories allergy;&#xD;
&#xD;
          3. Subjects with poor-controlled arterial hypertension (systolic blood pressure&gt; 140 mmHg&#xD;
             and diastolic blood pressure &gt; 90 mm Hg) despite standard medical management;&#xD;
&#xD;
          4. Serious cardiovascular disease: Ⅱ-level myocardial ischemia or myocardial infarction,&#xD;
             arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms);&#xD;
             III ~ IV level cardiac function insufficiency, or echocardiography showed that left&#xD;
             ventricular ejection fraction (LVEF &lt; 50%);&#xD;
&#xD;
          5. Patients with positive urinary protein (urine protein detection of 2 or more, or 24&#xD;
             hour urine protein &gt;1.0g);&#xD;
&#xD;
          6. Factors that could have an effect on oral medication (such as inability to swallow,&#xD;
             chronic diarrhea and intestinal obstruction);&#xD;
&#xD;
          7. Subjects with high gastrointestinal bleeding risk, including the following conditions:&#xD;
             local active ulcer lesions with positive fecal occult blood test (++); history of&#xD;
             black stool, or vomiting blood in the past 2 months;unresected primary lesion in&#xD;
             stomach with positive fecal occult blood test (+), ulcerated gastric carcinoma with&#xD;
             massive alimentary tract bleeding risk judged by PIs based on gastric endoscopy&#xD;
             result;&#xD;
&#xD;
          8. Abnormal Coagulation (INR&gt;1.5、APTT&gt;1.5 UNL), with tendency of bleed;&#xD;
&#xD;
          9. With psychotropic drug abuse history and can't get rid or with mental disorder&#xD;
             patients;&#xD;
&#xD;
         10. Less than 4 weeks from the last clinical trial;&#xD;
&#xD;
         11. According to the researcher's judgment, with other serious diseases which harm to&#xD;
             patient safety or affect patients complete the study;&#xD;
&#xD;
         12. Evidence of central nervous system(CNS) metastasis;&#xD;
&#xD;
         13. Pregnant or lactating women;&#xD;
&#xD;
         14. Other conditions regimented at investigators' discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rongbo Lin</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <last_update_submitted>October 13, 2018</last_update_submitted>
  <last_update_submitted_qc>October 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

